Infliximab Therapy for Crohn's Disease with a Reference to Mucosal Healing Takayuki Matsumoto 1 , Shinichiro Yada 1 , Shunichi Yanai 1 , Motohiro Esaki 1 , Hideki Koga 1 , Tomohiko Moriyama 1 , Shotaro Nakamura 1 , Mitsuo Iida 1 1Department of Medicine & Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Keyword: Crohn病 , infliximab , 粘膜治癒 pp.1819-1830
Published Date 2007/12/25
DOI https://doi.org/10.11477/mf.1403101237
  • Abstract
  • Look Inside
  • Reference

 We assessed the clinical activity indices and the mucosal healing in patients treated by scheduled maintenance therapy with infliximab. Among 27 patients treated by infliximab for more than a 30 week-period, the medication was more efficacious in patients with inflammatory disease than in those with fistulous disease. Among 10 patients in whom possible healing of the colorectal lesions could be evaluated by radiography or colonoscopy, active mucosal lesions in seven patients had healed, while those in the three other patients remained unchanged. The former patients were older than the latter patients. In three patients whose ileum could be assessed, the ileal lesions remained unchanged. The therapeutic effects of infliximab as determined by clinical activity indices and by mucosal lesions were unable to be associated in 7 of 10 patients examined. These observations suggest that scheduled maintenance therapy with infliximab is effective on mucosal lesions, as well as on clinical activities, in patients with Crohn's disease. The grade of mucosal healing, however, is presumably independent of clinical activities.

Copyright © 2007, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院